James Ward-Lilley

Vectura Group Ltd. engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.

Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany.

Part of Philip Morris International, Inc., Vectura Group Services Ltd. provides business support services. The company is based in London, UK.

Part of Philip Morris International, Inc., Vectura Ltd. is a leading inhalation CDMO that provides innovative inhaled drug development solutions to help bring medicines to market. The company is based in Chippenham, UK, and has planning permission for a new 10,000-square meter facility on Bristol & Bath Science Park - inhalation center of excellence. Vectura is reimagining healthcare and self-care, transforming the lives of airways disease patients. Founded in 1983, the British company specializes in formulation science, device technology, and inhaled development expertise to bring DPI, PMDI, and nebulizer medicines to market.

Founded in 2010, Vectura Group Investments Ltd. is a subsidiary of Philip Morris International, Inc. that manufactures products for airways diseases. The company is based in Chippenham, UK.

Aerogen Ltd. develops and manufactures aerosol products. It offers Aerogen Solo, Aerogen Ultra, Aerogen Pro, Pro-X controller and USB controller. The company was founded by John S. Power in 1997 and is headquartered in Galway, Ireland.